Needham & Company, LLC, a subsidiary of The Needham Group, Inc., is a nationally recognized investment banking and asset management firm focused solely on growth companies and their investors. Needham’s mission is to provide its clients with the long-term advice they need to achieve their business goals. The Firm's commitment to exceptional service is unusual in today’s business climate, and is born of a tradition which stresses integrity above all else. We strive to be front of mind, approachable and idea driven. Needham is actively engaged in the public and private capital markets, boasting a 30-year track record of executing complex transactions and the accompanying reputation for excellence in our markets.

Needham’s principal activities involve assisting our clients through a variety of advisory and transaction-related services, with a specific focus on:

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through HIF biology. Akebia's lead product candidate, AKB-6548, is a once-daily, oral therapy, which has completed a Phase 2b study for the treatment of anemia related to chronic kidney disease in non-dialysis patients and is also being tested in a Phase 2 study for the treatment of anemia in patients undergoing dialysis.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) raised $69.0 million in its follow-on offering at $8.25 per share. Needham acted as co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,090,909 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Akebia Therapeutics, Inc. to continue clinical development of AKB-6548 in patients with anemia secondary to chronic kidney disease, including the preparation for and initiation of Phase 3 trials, to advance its preclinical candidate, AKB-6899, through Phase 1 development in oncology, and to increase working capital, as well as for other general corporate purposes.

Pernix Therapeutics Holdings, Inc., is a specialty pharmaceutical company, that develops, manufactures, markets, and sells branded and generic pharmaceutical products. The company's product include CEDAX, an oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; Zutripro, Rezira, and Vituz for the relief of cough and nasal congestion; and OMECLAMOX-PAK a gastroenterology product. Its products also comprise Treximet, a medication indicated for the acute treatment of migraine attacks in adults; Silenor, a medication indicated for the treatment of insomnia characterized by difficulty with sleep maintenance; Khedezla, a prescription medication for major depressive disorder. In addition, the company offers various generic pharmaceutical products in the areas of nutritional supplements, analgesics, urinary tract, women's health, pre-natal vitamins, and dental health, as well as allergy, respiratory, iron deficiency, nephrology, and pain management. It serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies in the United States. The company was founded in 1996 and is headquartered in Morristown, New Jersey.

Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) issued $130.0 million principal amount of the Company's 4.25% Convertible Senior Notes due 2021Convertible Senior Notes due 2016. The size of the offering was increased from the previously announced aggregate principal amount of $120 million. The notes will pay interest semi-annually at a rate of 4.25% per annum and will mature on April 1, 2021, unless redeemed, repurchased or converted in accordance with their terms prior to such date. The notes will have an initial conversion rate, subject to adjustment, of 87.2030 shares of the Company’s common stock per $1,000 principal amount of the notes, representing a conversion price of approximately $11.47 per share of the Company’s common stock, based on the last reported sale price of $8.34 per share of the Company’s common stock on April 16, 2015. Needham & Company acted as a co-manager for this transaction. Pernix Therapeutics expects to use $80.9 million of the gross proceeds from the offering to finance the cash consideration portion of the consideration necessary to consummate its previously announced acquisition of the Zohydro® ER franchise, approximately $8.3 million to pay fees and expenses related to such acquisition and the offering, up to $2.2 million to pay the consent fee related to the Company’s previously announced consent solicitation of its 12.00% senior secured notes due 2020 and the remainder for working capital and other general corporate purposes, including to fund possible acquisitions of, or investments in, complementary businesses, products, services and technologies.

Cidara Therapeutics, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard-of-care therapies. Cidara's initial portfolio is comprised of a long-acting echinocandin antifungal product candidate, CD101 IV, and CD101 topical, for the treatment of serious fungal infections. In addition, Cidara has developed a proprietary immunotherapy platform, Cloudbreak™, designed to create compounds that direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. Cidara is headquartered in San Diego, California.

Cidara Therapeutics raised $76.8 million in its upsized initial public offering at $16.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares will be used by Cidara Therapeutics for general corporate purposes including working capital, product development and operating expenses.

Cradlepoint is the global leader in cloud-managed 4G LTE networking solutions, providing industry-leading WWAN and Security solutions to distributed enterprises. Specializing in Business Continuity, M2M/IoT applications, Application Specific or Parallel Networking and Transportation networking, Cradlepoint's award-winning solutions are purpose built for PCI-compliant networks. Cradlepoint was the first to pioneer and fully enable high-speed LTE solutions to maximize the potential of the cloud for businesses worldwide. Cradlepoint is a privately held company in Boise, Idaho.

Cradlepoint completed the pricing of a Series B round of $48 million in growth equity funding. Needham & Company served as sole placement agent on this transaction. The proceeds will be used to accelerate Cradlepoint’s international expansion and development of cloud-managed Wireless Wide Area Networks (WWAN) and security solutions.

Dyax Corp. is a biopharmaceutical company focused on: Hereditary Angioedema and Other Plasma-Kallikrein-Mediated (PKM)Disorders. It develops and commercializes treatments for hereditary angioedema and Dyax Corp. is working to identify additional disorders that are mediated by plasma kallikrein.

Dyax Corp. (NASDAQ: DYAX) raised $229.8 million in its follow-on offering at $27.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,110,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Dyax Corp. for to develop and, if approved, commercialize DX-2930 worldwide for the prophylactic treatment of hereditary angioedema, for research and development of product candidates to address additional plasma-kallikrein-mediated (PKM) disorders and other orphan diseases outside the PKM pathway, to prepay all of the debt outstanding under the loan agreement with LFRP Investors, L.P., an affiliate of HealthCare Royalty Partners, and for general corporate purposes.

Nova Measuring Instrument Ltd. delivers continuous innovation by providing advanced optical metrology solutions for the semiconductor manufacturing industry. Deployed with the world's largest integrated-circuit manufacturers, Nova's products deliver state-of-the-art, high-performance metrology solutions for effective process control throughout the semiconductor fabrication lifecycle. Nova's product portfolio, which combines high-precision hardware and cutting-edge software, supports the development and production of the most advanced devices in today's high-end semiconductor market. Nova's technical innovation and market leadership enable customers to improve process performance, enhance products' yields and accelerate time to market. Nova acts as a partner to semiconductor manufacturers from its offices around the world.

Nova Measuring Instrument Ltd. (NASDAQ: NVMI) announced that it has completed the acquisition of ReVera Incorporated, a leading provider of materials metrology solutions for complex, multi-layer film stacks for advanced node semiconductor manufacturing for a net purchase price of $46.5 million in cash. Needham & Company acted as a financial advisor as part of its services. The synergy between Nova’s Optical CD technology and ReVera’s unique X-Ray Photoelectron Spectroscopy (XPS) technology will deliver leading edge solutions for superior process control at the most advanced technology nodes.

Kornit Digital Ltd. develops, designs and markets innovative digital printing solutions for the global printed textile industry. Kornit's solution includes its proprietary digital printing systems, ink and other consumables, associated software and value added services. Kornit's vision is to revolutionize the textile industry by facilitating the transition from analog processes that have not evolved for decades to digital methods of production that address contemporary supply, demand and environmental dynamics. Kornit is a global company headquartered in Rosh-Ha`Ayin, Israel, with U.S. offices in Mequon, Wisconsin and additional sales, support and marketing offices in Germany and Hong Kong.

Kornit Digital Ltd. (NASDAQ: KRNT) raised $81.7 million in its initial public offering at $10.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,065,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Kornit Digital for general corporate purposes including working capital, to increase our visibility in the marketplace, to create a public market for our ordinary shares and to facilitate our future access to the public equity markets.

SolarEdge provides an intelligent inverter solution that has changed the way power is harvested and managed in solar photovoltaic systems. The SolarEdge DC optimized inverter system maximizes power generation at the individual PV module-level while lowering the cost of energy produced by the solar PV system. The SolarEdge system consists of power optimizers, inverters and a cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations.

SolarEdge Technologies (NASDAQ: SEDG) raised $144.9 million in its initial public offering at $18.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,050,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by SolarEdge Technologies for general corporate purposes, including working capital and expansion of their business into additional markets.

BEEcube is a technology innovator and leading supplier of advanced all programmable real-time signal processing platforms used in communications, defense, education and research for real-time prototyping, academic research, military communications, surveillance/signal intelligence and advanced wireless research/5G and infrastructure deployment. BEEcube will operate as a wholly-owned NI subsidiary going forward.

BEEcube, a technology innovator and leading supplier of high-performance FPGA prototyping and deployment products for advanced wireless research, completed its previously announced sale to National Instruments (NASDAQ: NATI)., the provider of platform-based systems that enable engineers and scientists to solve the world’s greatest engineering challenges. BEEcube will operate as a wholly-owned NI subsidiary. The terms of the transaction have not been publicly disclosed. Needham acted as financial advisor to BEEcube on this transaction.

Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers.

Esperion Therapeutics, Inc. (NASDAQ: ESPR) raised $201.3 million in its follow-on offering at $100.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 262,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering as well as its other existing capital resources, will be used by Esperion Therapeutics, Inc. to complete the clinical development of ETC-1002, including development of a fixed-dose combination of ETC-1002 and ezetimibe for statin intolerant patients, pre-commercial launch activities for ETC-1002 in the statin intolerant patient population, the initiation of a cardiovascular outcomes trial for high-risk patients who have had a cardiovascular event, working capital, and for general corporate and administrative expenses.

HubSpot is the world’s leading inbound marketing and sales platform. Since 2006, HubSpot has been on a mission to make the world more inbound. Today, over 12,000 customers in more than 75 countries use HubSpot’s software, services, and support to transform the way they attract, engage, and delight customers. HubSpot’s inbound marketing software, ranked #1 in customer satisfaction by VentureBeat and G2Crowd, includes social media publishing and monitoring, blogging, SEO, website content management, email marketing, marketing automation, and reporting and analytics, all in one integrated platform. Sidekick, HubSpot’s award-winning sales application, enables sales and service teams to have more effective conversations with leads, prospects, and customers. HubSpot is headquartered in Cambridge, MA with an office in Dublin, Ireland, and has been recognized by Inc., Forbes, and Deloitte as one of the world’s fastest-growing companies.

HubSpot, Inc. (NYSE: HUBS) raised $175.1 million in its follow-on offering at $37.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 617,172 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by HubSpot, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy.

Genocea Biosciences, Inc. (NASDAQ: GNCA) raised $51.75 million in its follow-on offering at $8.25 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 818,181 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Genocea Biosciences primarily for preclinical and clinical development of our lead product candidates, discovery, research and development of other product candidates and other corporate purposes.

Mandalay Digital Group, Inc., through its wholly owned subsidiary, Digital Turbine, provides mobile solutions for wireless carriers globally to enable them to better monetize mobile content. The Company's products include mobile application management through DT Ignite, user experience and discovery through DT IQ, application stores and content through DT Marketplace, and content management and mobile payments through DT Pay. With global headquarters in Los Angeles, and offices in the U.S., Asia Pacific and EMEA, Mandalay Digital's solutions are used by more than 31 million consumers each month across more than 20 global operators.

Mandalay Digital Group (Nasdaq:MNDL) announced that it has completed the acquisition of Appia, the leading independent mobile user acquisition network, in a stock-for-stock transaction. Appia shareholders received approximately 19 million shares of newly issued Digital Turbine stock, or approximately 33% of the combined company. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of Mandalay Digital Group as part of its services.

Vector Capital is a leading global private equity firm specializing in transformational investments in established technology businesses. Vector identifies and pursues these investments in both the private and public markets. Vector actively partners with management teams to devise and execute new financial and business strategies that materially improve the competitive standing of these businesses and enhance their value for employees, customers and shareholders. Among Vector's notable investments are Aladdin Knowledge Systems, Allegro Development, Cambium Networks, Certara, CollabNet, Corel, IPVALUE Management, LANDesk Software, Niku, Gerber Scientific, RAE Systems, Register.com, Saba, SafeNet, Technicolor, Teletrac, Tidel, Triton Digital, WatchGuard Technologies and WinZip.

Vector Capital announced that it has completed the acquisition of ChyronHego Corporation, a leading provider in broadcast graphics creation, play-out and real-time data visualization offering a wide variety of products and services for live television, news and sports production, for a net purchase price of $120 million in cash. Needham & Company acted as a financial advisor to Vector Capital on this transaction.

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, we are building a diversified portfolio of ophthalmic products that can help people to enhance their sight. Nicox’s advanced pipeline features two pre-NDA candidates (Vesneo™ for glaucoma, partnered with Bausch + Lomb / Valeant and AC-170 for allergic conjunctivitis) as well as two pre-MAA candidates (AzaSite® for bacterial conjunctivitis and BromSite™ for pain and inflammation after cataract surgery). The Group operates directly in six countries, including the United States. It has proprietary commercial operations in Europe’s five largest markets complemented by an expanding international network of distributors.
Nicox is headquartered in France.

Nicox S.A. (Euronext Paris: COX) completed the pricing financing of 15 million shares at €1.80, for gross proceeds of approximately €27 million or $28.53 million through a private placement made to specific categories of investors. Needham acted as co-placement agent for this transaction. The net proceeds from the sale of the shares will be used by Nicox to provide additional resources to the Company to finance its strategy, in particular:
*Working capital and general corporate purposes.
*Clinical development and regulatory filings related to pipeline candidates.
*Strengthening the Company’s commercial organization in Europe and the United States.
*Listing of new shares.

MaxPoint provides a leading business intelligence and digital marketing solution that enables national brands to drive local, in-store sales. The company’s proprietary Digital Zip® technology and the MaxPoint Intelligence Platform predict the most likely local buyers of a specific product at a particular retail location and then execute cross-channel digital marketing campaigns to reach these buyers. MaxPoint has worked with each of the top 20 leading national advertisers and each of the top 10 advertising agencies in the United States as ranked by Advertising Age.

MaxPoint Interactive, Inc. (NYSE: MXPT) raised $74.8 million in its initial public offering at $11.50 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares will be used by MaxPoint Interactive for general corporate purposes, including working capital, sales and marketing activities, engineering initiatives including enhancement of our solution, investment in technology and development and capital expenditures.

Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection.

Summit Therapeutics (NASDAQ: SMMT) raised $39.3 million in its initial public offering at $9.90 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 517,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Summit Therapeutics for general corporate purposes including working capital, product development and operating expenses.

Q2 is a leading provider of secure, cloud-based virtual banking solutions headquartered in Austin, Texas. Q2 enables regional and community financial institutions, or RCFIs, to deliver a robust suite of integrated virtual banking services and engage more effectively with their retail and commercial account holders who expect to bank anytime, anywhere and on any device. Q2 solutions are often the most frequent point of interaction between its RCFI customers and their account holders. As such, Q2 purpose-built its solutions to deliver a compelling, consistent user experience across digital channels and drive the success of its customers by extending their local brands, enabling improved account holder retention and creating incremental sales opportunities.

Q2 Holdings, Inc. (NYSE: QTWO) raised $116.34 million in its upsized follow-on offering at $19.75 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 768,352 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the Q2 Holdings for working capital and other general corporate purposes, including
to finance their expected growth, develop new technologies, fund capital expenditures, or expand the company's existing business through investments in or acquisitions of other businesses or technologies.

Quintic is the supplier of QBlue, a world class Bluetooth Low Energy product line. Leveraging their expertise in ultra-low power and high performance RF IC design, Quintic is delivering leading wireless connectivity and control solutions for consumer electronics, wearable devices and their peripherals.

Quintic Microelectronics completed its previously announced sale of its assets and IP related to its Wearable and Bluetooth Low Energy (BTLE) IC business to NXP semiconductors N.V. (NASDAQ: NXPI), creator of solutions that enable secure connections for a smarter world. The transaction contributes to NXP’s drive to create security and connectivity solutions for Internet-of-Things applications in Health & Fitness Wearables, Mobile Transactions, Proximity Marketing, Smart Home and Automotive. Terms of the deal were not disclosed. Needham & Company served as exclusive financial advisor to Quintic on this transaction.

3D Systems is pioneering 3D design and fabrication for everyone. 3DS provides the most advanced and comprehensive solutions including 3D printers, print materials and cloud sourced custom parts. Its powerful ecosystem empowers professionals and consumers everywhere to bring their ideas to life in material choices including plastics, metals, ceramics and edibles. 3DS' leading 3D healthcare solutions include end-to-end simulation, training and planning and printing of surgical instruments and devices for personalized surgery and patient specific medical and dental devices. Its democratized 3D digital design, fabrication and inspection products provide seamless interoperability between subtractive and additive manufacturing and incorporate the latest immersive computing technologies. Its products and services replace and complement traditional methods with improved results and reduced time to outcomes. These solutions are used to rapidly design, create, communicate, plan, guide, prototype or produce functional parts, devices and assemblies, empowering customers to manufacture the future.

3D Systems (NYSE:DDD), is a leading global provider of 3D content-to-print solutions including 3D printers, print materials and on-demand custom parts services for professionals and consumers alike announced that it has completed the acquisition of Cimatron Ltd. (Nasdaq:CIMT), a leading provider of integrated CAD/CAM software solutions for the toolmaking and manufacturing industries for approximately $97 million, inclusive of Cimatron's net cash. Needham & Company served as exclusive financial advisor to 3D Systems on this transaction.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and other diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). OCA has received breakthrough therapy designation from the FDA for the treatment of NASH with fibrosis. OCA has also received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan, China and Korea, where it has out-licensed the product candidate to Sumitomo Dainippon Pharma.

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) raised $202.4 million in its follow-on offering at $176.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 150,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Intercept Pharmaceuticals for additional funding of ongoing clinical trials, general corporate purposes including working capital and operating expenses.

Oerlikon is a globally leading company in the field of surface solutions, manmade fibers, drive systems and vacuum generation. Based on these core competencies, Oerlikon develops production systems, components, and services for high-technology products. The company's commercial activities center on turn-key solutions for the manufacturing of protective coatings for precision tools and components (Surface Solutions Segment), systems for producing vacuums and conveying process gases (Vacuum Segment), equipment for textile production (Manmade Fibers Segment) and propulsion technology (Drive Systems Segment).

OC Oerlikon Corporation AG (SIX: OERL), a globally leading company in the field of surface solutions, manmade fibers, drive systems and vacuum generation, announced the successful closing of the sale of its Advanced Technologies Segment to Evatec AG, a customer-focused business which produces its thin-film deposition products to the highest standards. Both capital equipment businesses are well positioned in their respective markets by delivering complete thin film production solutions and services to their customers around the globe. Terms of the deal were not disclosed. Needham & Company served as exclusive financial advisor to Oerlikon on this transaction.

BTU International, Inc. is global supplier and technology leader of advanced thermal processing equipment and processes to the electronics and alternative energy manufacturing markets. BTU equipment is used in the production of printed circuit board assemblies and semiconductor packaging as well as in solar cell and nuclear fuel manufacturing.

BTU International, Inc. (NASDAQ: BTUI), a global supplier of advanced thermal processing equipment to the electronics and alternative energy manufacturing markets, completed its previously announced sale to Amtech Systems, Inc. (NASDAQ: ASYS), a global supplier of production and automation systems and related supplies for the manufacture of solar cells, semiconductors, and sapphire and silicon wafers. Under the terms of the merger agreement, BTU shareholders received 0.3291 shares of Amtech common stock per share of BTU common stock. The transaction valued BTU at approximately $26.2 million based on Amtech’s close price on Friday, January 30, 2015. Needham & Company acted as exclusive financial advisor to BTU International on the transaction.

NeuLion, Inc. offers the true end-to-end solution for delivering live and on-demand content to Internet-enabled devices. NeuLion enables content owners and distributors, cable operators and telecommunications companies to capitalize on the massive consumer demand for viewing video content on PCs, smartphones, iPads and other similar devices. NeuLion's customers include major entertainment, sports, global content and news companies. NeuLion is based in Plainview, NY.

NeuLion, Inc. (TSX: NLN), the leading enabler and provider of live and on-demand content to Internet-connected devices, announced that it has completed the acquisition of DivX Corporation, a leading provider of next-generation digital video solutions. The total transaction value is approximately $62.5 million. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of NeuLion, Inc. as part of its services.

Omeros Corporation is a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.

Omeros Corporation (NASDAQ: OMER) raised $84 million in its follow-on offering at $20.03 per share of its common stock at a per share price to the public equal to $20.03, and pre-funded warrants to purchase up to 749,250 shares of its common stock, at a per warrant price to the public equal to $20.02. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 449,325 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Omeros Corporation for general corporate purposes, including expenses related to the commercialization of Omidria™, research and development expenses, such as funding clinical trials, preclinical studies, manufacturing development and costs associated with otherwise advancing the company's drug candidates toward New Drug Application submission. Omeros may also use the net proceeds for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies that are complementary to its own, and other capital expenditures.

TRACON Pharmaceuticals, Inc. develops targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available therapies.

TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) raised $36 million in its initial public offering at $10.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares will be used by TRACON Pharmaceuticals for additional funding of ongoing clinical trials, general corporate purposes including working capital and operating expenses.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam’s pipeline of investigational RNAi therapeutics is focused in 3 Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) raised $517.5 million in its follow-on offering at $95 per share. Needham acted as the co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 710,526 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Alnylam Pharmaceuticals for general corporate purposes, focused on achieving its Alnylam 2020 profile with 3 marketed products, 10 RNAi therapeutic clinical programs, including 4 in late stages of development, across its 3 Strategic Therapeutic Areas, or “STArs” – Genetic Medicines, Cardio-Metabolic Disease, and Hepatic Infectious Disease – by the end of 2020.

Sanbolic, an innovator and leader in workload-oriented storage virtualization technologies, completed its previously announced sale to Citrix Systems, Inc. (NASDAQ: CTXS), a leader in mobile workspaces, providing virtualization, mobility management, networking and cloud services to enable new ways to work better. The terms of the acquisition were not disclosed. Needham & Company served as exclusive financial advisor to Sanbolic on this transaction.

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/A

N/a

N/A

N/A

N/A

N/A

N/A

N/A

N/A

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through HIF biology. Akebia's lead product candidate, AKB-6548, is a once-daily, oral therapy, which has completed a Phase 2b study for the treatment of anemia related to chronic kidney disease in non-dialysis patients and is also being tested in a Phase 2 study for the treatment of anemia in patients undergoing dialysis.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) raised $69.0 million in its follow-on offering at $8.25 per share. Needham acted as co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,090,909 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Akebia Therapeutics, Inc. to continue clinical development of AKB-6548 in patients with anemia secondary to chronic kidney disease, including the preparation for and initiation of Phase 3 trials, to advance its preclinical candidate, AKB-6899, through Phase 1 development in oncology, and to increase working capital, as well as for other general corporate purposes.

Pernix Therapeutics Holdings, Inc., is a specialty pharmaceutical company, that develops, manufactures, markets, and sells branded and generic pharmaceutical products. The company's product include CEDAX, an oral cephalosporin used for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, middle ear infection due to haemophilus influenza, or streptococcus pyogene; Zutripro, Rezira, and Vituz for the relief of cough and nasal congestion; and OMECLAMOX-PAK a gastroenterology product. Its products also comprise Treximet, a medication indicated for the acute treatment of migraine attacks in adults; Silenor, a medication indicated for the treatment of insomnia characterized by difficulty with sleep maintenance; Khedezla, a prescription medication for major depressive disorder. In addition, the company offers various generic pharmaceutical products in the areas of nutritional supplements, analgesics, urinary tract, women's health, pre-natal vitamins, and dental health, as well as allergy, respiratory, iron deficiency, nephrology, and pain management. It serves drug wholesalers, retail drug stores, mass merchandisers, and grocery store pharmacies in the United States. The company was founded in 1996 and is headquartered in Morristown, New Jersey.

Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) issued $130.0 million principal amount of the Company's 4.25% Convertible Senior Notes due 2021Convertible Senior Notes due 2016. The size of the offering was increased from the previously announced aggregate principal amount of $120 million. The notes will pay interest semi-annually at a rate of 4.25% per annum and will mature on April 1, 2021, unless redeemed, repurchased or converted in accordance with their terms prior to such date. The notes will have an initial conversion rate, subject to adjustment, of 87.2030 shares of the Company’s common stock per $1,000 principal amount of the notes, representing a conversion price of approximately $11.47 per share of the Company’s common stock, based on the last reported sale price of $8.34 per share of the Company’s common stock on April 16, 2015. Needham & Company acted as a co-manager for this transaction. Pernix Therapeutics expects to use $80.9 million of the gross proceeds from the offering to finance the cash consideration portion of the consideration necessary to consummate its previously announced acquisition of the Zohydro® ER franchise, approximately $8.3 million to pay fees and expenses related to such acquisition and the offering, up to $2.2 million to pay the consent fee related to the Company’s previously announced consent solicitation of its 12.00% senior secured notes due 2020 and the remainder for working capital and other general corporate purposes, including to fund possible acquisitions of, or investments in, complementary businesses, products, services and technologies.

Cidara Therapeutics, Inc. is a biotechnology company focused on the discovery, development and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard-of-care therapies. Cidara's initial portfolio is comprised of a long-acting echinocandin antifungal product candidate, CD101 IV, and CD101 topical, for the treatment of serious fungal infections. In addition, Cidara has developed a proprietary immunotherapy platform, Cloudbreak™, designed to create compounds that direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. Cidara is headquartered in San Diego, California.

Cidara Therapeutics raised $76.8 million in its upsized initial public offering at $16.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares will be used by Cidara Therapeutics for general corporate purposes including working capital, product development and operating expenses.

Cradlepoint is the global leader in cloud-managed 4G LTE networking solutions, providing industry-leading WWAN and Security solutions to distributed enterprises. Specializing in Business Continuity, M2M/IoT applications, Application Specific or Parallel Networking and Transportation networking, Cradlepoint's award-winning solutions are purpose built for PCI-compliant networks. Cradlepoint was the first to pioneer and fully enable high-speed LTE solutions to maximize the potential of the cloud for businesses worldwide. Cradlepoint is a privately held company in Boise, Idaho.

Cradlepoint completed the pricing of a Series B round of $48 million in growth equity funding. Needham & Company served as sole placement agent on this transaction. The proceeds will be used to accelerate Cradlepoint’s international expansion and development of cloud-managed Wireless Wide Area Networks (WWAN) and security solutions.

Dyax Corp. is a biopharmaceutical company focused on: Hereditary Angioedema and Other Plasma-Kallikrein-Mediated (PKM)Disorders. It develops and commercializes treatments for hereditary angioedema and Dyax Corp. is working to identify additional disorders that are mediated by plasma kallikrein.

Dyax Corp. (NASDAQ: DYAX) raised $229.8 million in its follow-on offering at $27.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,110,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Dyax Corp. for to develop and, if approved, commercialize DX-2930 worldwide for the prophylactic treatment of hereditary angioedema, for research and development of product candidates to address additional plasma-kallikrein-mediated (PKM) disorders and other orphan diseases outside the PKM pathway, to prepay all of the debt outstanding under the loan agreement with LFRP Investors, L.P., an affiliate of HealthCare Royalty Partners, and for general corporate purposes.

Nova Measuring Instrument Ltd. delivers continuous innovation by providing advanced optical metrology solutions for the semiconductor manufacturing industry. Deployed with the world's largest integrated-circuit manufacturers, Nova's products deliver state-of-the-art, high-performance metrology solutions for effective process control throughout the semiconductor fabrication lifecycle. Nova's product portfolio, which combines high-precision hardware and cutting-edge software, supports the development and production of the most advanced devices in today's high-end semiconductor market. Nova's technical innovation and market leadership enable customers to improve process performance, enhance products' yields and accelerate time to market. Nova acts as a partner to semiconductor manufacturers from its offices around the world.

Nova Measuring Instrument Ltd. (NASDAQ: NVMI) announced that it has completed the acquisition of ReVera Incorporated, a leading provider of materials metrology solutions for complex, multi-layer film stacks for advanced node semiconductor manufacturing for a net purchase price of $46.5 million in cash. Needham & Company acted as a financial advisor as part of its services. The synergy between Nova’s Optical CD technology and ReVera’s unique X-Ray Photoelectron Spectroscopy (XPS) technology will deliver leading edge solutions for superior process control at the most advanced technology nodes.

Kornit Digital Ltd. develops, designs and markets innovative digital printing solutions for the global printed textile industry. Kornit's solution includes its proprietary digital printing systems, ink and other consumables, associated software and value added services. Kornit's vision is to revolutionize the textile industry by facilitating the transition from analog processes that have not evolved for decades to digital methods of production that address contemporary supply, demand and environmental dynamics. Kornit is a global company headquartered in Rosh-Ha`Ayin, Israel, with U.S. offices in Mequon, Wisconsin and additional sales, support and marketing offices in Germany and Hong Kong.

Kornit Digital Ltd. (NASDAQ: KRNT) raised $81.7 million in its initial public offering at $10.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,065,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Kornit Digital for general corporate purposes including working capital, to increase our visibility in the marketplace, to create a public market for our ordinary shares and to facilitate our future access to the public equity markets.

SolarEdge provides an intelligent inverter solution that has changed the way power is harvested and managed in solar photovoltaic systems. The SolarEdge DC optimized inverter system maximizes power generation at the individual PV module-level while lowering the cost of energy produced by the solar PV system. The SolarEdge system consists of power optimizers, inverters and a cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations.

SolarEdge Technologies (NASDAQ: SEDG) raised $144.9 million in its initial public offering at $18.00 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 1,050,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by SolarEdge Technologies for general corporate purposes, including working capital and expansion of their business into additional markets.

BEEcube is a technology innovator and leading supplier of advanced all programmable real-time signal processing platforms used in communications, defense, education and research for real-time prototyping, academic research, military communications, surveillance/signal intelligence and advanced wireless research/5G and infrastructure deployment. BEEcube will operate as a wholly-owned NI subsidiary going forward.

BEEcube, a technology innovator and leading supplier of high-performance FPGA prototyping and deployment products for advanced wireless research, completed its previously announced sale to National Instruments (NASDAQ: NATI)., the provider of platform-based systems that enable engineers and scientists to solve the world’s greatest engineering challenges. BEEcube will operate as a wholly-owned NI subsidiary. The terms of the transaction have not been publicly disclosed. Needham acted as financial advisor to BEEcube on this transaction.

Esperion Therapeutics, Inc. is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers.

Esperion Therapeutics, Inc. (NASDAQ: ESPR) raised $201.3 million in its follow-on offering at $100.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 262,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering as well as its other existing capital resources, will be used by Esperion Therapeutics, Inc. to complete the clinical development of ETC-1002, including development of a fixed-dose combination of ETC-1002 and ezetimibe for statin intolerant patients, pre-commercial launch activities for ETC-1002 in the statin intolerant patient population, the initiation of a cardiovascular outcomes trial for high-risk patients who have had a cardiovascular event, working capital, and for general corporate and administrative expenses.

HubSpot is the world’s leading inbound marketing and sales platform. Since 2006, HubSpot has been on a mission to make the world more inbound. Today, over 12,000 customers in more than 75 countries use HubSpot’s software, services, and support to transform the way they attract, engage, and delight customers. HubSpot’s inbound marketing software, ranked #1 in customer satisfaction by VentureBeat and G2Crowd, includes social media publishing and monitoring, blogging, SEO, website content management, email marketing, marketing automation, and reporting and analytics, all in one integrated platform. Sidekick, HubSpot’s award-winning sales application, enables sales and service teams to have more effective conversations with leads, prospects, and customers. HubSpot is headquartered in Cambridge, MA with an office in Dublin, Ireland, and has been recognized by Inc., Forbes, and Deloitte as one of the world’s fastest-growing companies.

HubSpot, Inc. (NYSE: HUBS) raised $175.1 million in its follow-on offering at $37.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 617,172 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by HubSpot, Inc. for general corporate purposes, which may include working capital, capital expenditures, other corporate expenses, and acquisitions of complementary products, technologies or businesses.

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS™, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for HSV-2 therapy, GEN-004 to prevent infections caused by pneumococcus, and earlier-stage programs in chlamydia, HSV-2 prophylaxis, malaria and cancer immunotherapy.

Genocea Biosciences, Inc. (NASDAQ: GNCA) raised $51.75 million in its follow-on offering at $8.25 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 818,181 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Genocea Biosciences primarily for preclinical and clinical development of our lead product candidates, discovery, research and development of other product candidates and other corporate purposes.

Mandalay Digital Group, Inc., through its wholly owned subsidiary, Digital Turbine, provides mobile solutions for wireless carriers globally to enable them to better monetize mobile content. The Company's products include mobile application management through DT Ignite, user experience and discovery through DT IQ, application stores and content through DT Marketplace, and content management and mobile payments through DT Pay. With global headquarters in Los Angeles, and offices in the U.S., Asia Pacific and EMEA, Mandalay Digital's solutions are used by more than 31 million consumers each month across more than 20 global operators.

Mandalay Digital Group (Nasdaq:MNDL) announced that it has completed the acquisition of Appia, the leading independent mobile user acquisition network, in a stock-for-stock transaction. Appia shareholders received approximately 19 million shares of newly issued Digital Turbine stock, or approximately 33% of the combined company. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of Mandalay Digital Group as part of its services.

Vector Capital is a leading global private equity firm specializing in transformational investments in established technology businesses. Vector identifies and pursues these investments in both the private and public markets. Vector actively partners with management teams to devise and execute new financial and business strategies that materially improve the competitive standing of these businesses and enhance their value for employees, customers and shareholders. Among Vector's notable investments are Aladdin Knowledge Systems, Allegro Development, Cambium Networks, Certara, CollabNet, Corel, IPVALUE Management, LANDesk Software, Niku, Gerber Scientific, RAE Systems, Register.com, Saba, SafeNet, Technicolor, Teletrac, Tidel, Triton Digital, WatchGuard Technologies and WinZip.

Vector Capital announced that it has completed the acquisition of ChyronHego Corporation, a leading provider in broadcast graphics creation, play-out and real-time data visualization offering a wide variety of products and services for live television, news and sports production, for a net purchase price of $120 million in cash. Needham & Company acted as a financial advisor to Vector Capital on this transaction.

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, we are building a diversified portfolio of ophthalmic products that can help people to enhance their sight. Nicox’s advanced pipeline features two pre-NDA candidates (Vesneo™ for glaucoma, partnered with Bausch + Lomb / Valeant and AC-170 for allergic conjunctivitis) as well as two pre-MAA candidates (AzaSite® for bacterial conjunctivitis and BromSite™ for pain and inflammation after cataract surgery). The Group operates directly in six countries, including the United States. It has proprietary commercial operations in Europe’s five largest markets complemented by an expanding international network of distributors.
Nicox is headquartered in France.

Nicox S.A. (Euronext Paris: COX) completed the pricing financing of 15 million shares at €1.80, for gross proceeds of approximately €27 million or $28.53 million through a private placement made to specific categories of investors. Needham acted as co-placement agent for this transaction. The net proceeds from the sale of the shares will be used by Nicox to provide additional resources to the Company to finance its strategy, in particular:
*Working capital and general corporate purposes.
*Clinical development and regulatory filings related to pipeline candidates.
*Strengthening the Company’s commercial organization in Europe and the United States.
*Listing of new shares.

MaxPoint provides a leading business intelligence and digital marketing solution that enables national brands to drive local, in-store sales. The company’s proprietary Digital Zip® technology and the MaxPoint Intelligence Platform predict the most likely local buyers of a specific product at a particular retail location and then execute cross-channel digital marketing campaigns to reach these buyers. MaxPoint has worked with each of the top 20 leading national advertisers and each of the top 10 advertising agencies in the United States as ranked by Advertising Age.

MaxPoint Interactive, Inc. (NYSE: MXPT) raised $74.8 million in its initial public offering at $11.50 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares will be used by MaxPoint Interactive for general corporate purposes, including working capital, sales and marketing activities, engineering initiatives including enhancement of our solution, investment in technology and development and capital expenditures.

Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease Clostridium difficile infection.

Summit Therapeutics (NASDAQ: SMMT) raised $39.3 million in its initial public offering at $9.90 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 517,500 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares will be used by Summit Therapeutics for general corporate purposes including working capital, product development and operating expenses.

Q2 is a leading provider of secure, cloud-based virtual banking solutions headquartered in Austin, Texas. Q2 enables regional and community financial institutions, or RCFIs, to deliver a robust suite of integrated virtual banking services and engage more effectively with their retail and commercial account holders who expect to bank anytime, anywhere and on any device. Q2 solutions are often the most frequent point of interaction between its RCFI customers and their account holders. As such, Q2 purpose-built its solutions to deliver a compelling, consistent user experience across digital channels and drive the success of its customers by extending their local brands, enabling improved account holder retention and creating incremental sales opportunities.

Q2 Holdings, Inc. (NYSE: QTWO) raised $116.34 million in its upsized follow-on offering at $19.75 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 768,352 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the Q2 Holdings for working capital and other general corporate purposes, including
to finance their expected growth, develop new technologies, fund capital expenditures, or expand the company's existing business through investments in or acquisitions of other businesses or technologies.

Quintic is the supplier of QBlue, a world class Bluetooth Low Energy product line. Leveraging their expertise in ultra-low power and high performance RF IC design, Quintic is delivering leading wireless connectivity and control solutions for consumer electronics, wearable devices and their peripherals.

Quintic Microelectronics completed its previously announced sale of its assets and IP related to its Wearable and Bluetooth Low Energy (BTLE) IC business to NXP semiconductors N.V. (NASDAQ: NXPI), creator of solutions that enable secure connections for a smarter world. The transaction contributes to NXP’s drive to create security and connectivity solutions for Internet-of-Things applications in Health & Fitness Wearables, Mobile Transactions, Proximity Marketing, Smart Home and Automotive. Terms of the deal were not disclosed. Needham & Company served as exclusive financial advisor to Quintic on this transaction.

3D Systems is pioneering 3D design and fabrication for everyone. 3DS provides the most advanced and comprehensive solutions including 3D printers, print materials and cloud sourced custom parts. Its powerful ecosystem empowers professionals and consumers everywhere to bring their ideas to life in material choices including plastics, metals, ceramics and edibles. 3DS' leading 3D healthcare solutions include end-to-end simulation, training and planning and printing of surgical instruments and devices for personalized surgery and patient specific medical and dental devices. Its democratized 3D digital design, fabrication and inspection products provide seamless interoperability between subtractive and additive manufacturing and incorporate the latest immersive computing technologies. Its products and services replace and complement traditional methods with improved results and reduced time to outcomes. These solutions are used to rapidly design, create, communicate, plan, guide, prototype or produce functional parts, devices and assemblies, empowering customers to manufacture the future.

3D Systems (NYSE:DDD), is a leading global provider of 3D content-to-print solutions including 3D printers, print materials and on-demand custom parts services for professionals and consumers alike announced that it has completed the acquisition of Cimatron Ltd. (Nasdaq:CIMT), a leading provider of integrated CAD/CAM software solutions for the toolmaking and manufacturing industries for approximately $97 million, inclusive of Cimatron's net cash. Needham & Company served as exclusive financial advisor to 3D Systems on this transaction.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat orphan and more prevalent liver and other diseases utilizing its expertise in bile acid chemistry. The company's lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor (FXR). OCA is being developed for a variety of chronic liver diseases including primary biliary cirrhosis (PBC), nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). OCA has received breakthrough therapy designation from the FDA for the treatment of NASH with fibrosis. OCA has also received orphan drug designation in both the United States and Europe for the treatment of PBC and PSC. Intercept owns worldwide rights to OCA outside of Japan, China and Korea, where it has out-licensed the product candidate to Sumitomo Dainippon Pharma.

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) raised $202.4 million in its follow-on offering at $176.0 per share. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 150,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Intercept Pharmaceuticals for additional funding of ongoing clinical trials, general corporate purposes including working capital and operating expenses.

Oerlikon is a globally leading company in the field of surface solutions, manmade fibers, drive systems and vacuum generation. Based on these core competencies, Oerlikon develops production systems, components, and services for high-technology products. The company's commercial activities center on turn-key solutions for the manufacturing of protective coatings for precision tools and components (Surface Solutions Segment), systems for producing vacuums and conveying process gases (Vacuum Segment), equipment for textile production (Manmade Fibers Segment) and propulsion technology (Drive Systems Segment).

OC Oerlikon Corporation AG (SIX: OERL), a globally leading company in the field of surface solutions, manmade fibers, drive systems and vacuum generation, announced the successful closing of the sale of its Advanced Technologies Segment to Evatec AG, a customer-focused business which produces its thin-film deposition products to the highest standards. Both capital equipment businesses are well positioned in their respective markets by delivering complete thin film production solutions and services to their customers around the globe. Terms of the deal were not disclosed. Needham & Company served as exclusive financial advisor to Oerlikon on this transaction.

BTU International, Inc. is global supplier and technology leader of advanced thermal processing equipment and processes to the electronics and alternative energy manufacturing markets. BTU equipment is used in the production of printed circuit board assemblies and semiconductor packaging as well as in solar cell and nuclear fuel manufacturing.

BTU International, Inc. (NASDAQ: BTUI), a global supplier of advanced thermal processing equipment to the electronics and alternative energy manufacturing markets, completed its previously announced sale to Amtech Systems, Inc. (NASDAQ: ASYS), a global supplier of production and automation systems and related supplies for the manufacture of solar cells, semiconductors, and sapphire and silicon wafers. Under the terms of the merger agreement, BTU shareholders received 0.3291 shares of Amtech common stock per share of BTU common stock. The transaction valued BTU at approximately $26.2 million based on Amtech’s close price on Friday, January 30, 2015. Needham & Company acted as exclusive financial advisor to BTU International on the transaction.

NeuLion, Inc. offers the true end-to-end solution for delivering live and on-demand content to Internet-enabled devices. NeuLion enables content owners and distributors, cable operators and telecommunications companies to capitalize on the massive consumer demand for viewing video content on PCs, smartphones, iPads and other similar devices. NeuLion's customers include major entertainment, sports, global content and news companies. NeuLion is based in Plainview, NY.

NeuLion, Inc. (TSX: NLN), the leading enabler and provider of live and on-demand content to Internet-connected devices, announced that it has completed the acquisition of DivX Corporation, a leading provider of next-generation digital video solutions. The total transaction value is approximately $62.5 million. Needham & Company acted as a financial advisor and provided a fairness opinion to the Board of Directors of NeuLion, Inc. as part of its services.

Omeros Corporation is a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.

Omeros Corporation (NASDAQ: OMER) raised $84 million in its follow-on offering at $20.03 per share of its common stock at a per share price to the public equal to $20.03, and pre-funded warrants to purchase up to 749,250 shares of its common stock, at a per warrant price to the public equal to $20.02. Needham acted as a co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 449,325 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Omeros Corporation for general corporate purposes, including expenses related to the commercialization of Omidria™, research and development expenses, such as funding clinical trials, preclinical studies, manufacturing development and costs associated with otherwise advancing the company's drug candidates toward New Drug Application submission. Omeros may also use the net proceeds for working capital, the repayment of debt obligations, acquisitions or investments in businesses, products or technologies that are complementary to its own, and other capital expenditures.

TRACON Pharmaceuticals, Inc. develops targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of multiple solid tumor types, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. Both TRC105 and TRC102 are being developed for treatment in combination with currently available therapies.

TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) raised $36 million in its initial public offering at $10.00 per share. Needham acted as a co-manager on the transaction. The net proceeds from the sale of the shares will be used by TRACON Pharmaceuticals for additional funding of ongoing clinical trials, general corporate purposes including working capital and operating expenses.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines. Alnylam’s pipeline of investigational RNAi therapeutics is focused in 3 Strategic Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline of RNAi therapeutics for the treatment of rare diseases; Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases; and Hepatic Infectious Disease, with a pipeline of RNAi therapeutics that address the major global health challenges of hepatic infectious diseases.

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) raised $517.5 million in its follow-on offering at $95 per share. Needham acted as the co-manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 710,526 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Alnylam Pharmaceuticals for general corporate purposes, focused on achieving its Alnylam 2020 profile with 3 marketed products, 10 RNAi therapeutic clinical programs, including 4 in late stages of development, across its 3 Strategic Therapeutic Areas, or “STArs” – Genetic Medicines, Cardio-Metabolic Disease, and Hepatic Infectious Disease – by the end of 2020.

Sanbolic, an innovator and leader in workload-oriented storage virtualization technologies, completed its previously announced sale to Citrix Systems, Inc. (NASDAQ: CTXS), a leader in mobile workspaces, providing virtualization, mobility management, networking and cloud services to enable new ways to work better. The terms of the acquisition were not disclosed. Needham & Company served as exclusive financial advisor to Sanbolic on this transaction.